About this trial
Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.
Eligibility criteria
Qualifiers
Type 1 diabetes
Disqualifiers
patients with other autoimmune diseases
patients with micro or macro vascular complications
patients with other chronic diseases
Trial design
Treatments tested in this trial
- Insulin producing stem cells infusion